Gilead Sciences (GILD) Starts Phase 2 Clinical Trial Evaluating GS-7340 for HIV
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $66.16 -1.15%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 4.2%
Revenue Growth %: -0.6%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 4.2%
Revenue Growth %: -0.6%
Join SI Premium – FREE
Gilead Sciences, Inc. (Nasdaq: GILD) announced the initiation of a Phase 2 clinical trial evaluating GS-7340 for the treatment of HIV-1 infection in treatment-naïve adults. GS-7340 is a novel prodrug of tenofovir, the active agent in Viread® (tenofovir disoproxil fumarate). In previous studies, GS-7340 has demonstrated the ability to provide greater antiviral efficacy at a dose that is ten times lower than Viread.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) PT Lowered to $75 at UBS
- Ocular Therapeutix (OCUL) Appoints Pravin U. Dugel as CEO
- Sana Biotechnology (SANA) Announces Resignation of Douglas Williams
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
